Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis…
A number of therapies from a range of drug classes are available to treat the symptoms of narcolepsy (e.g., excessive daytime sleepiness, cataplexy). Our Treatment Algorithms research leverages…
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis…
DRG Epidemiology’s coverage of systemic lupus erythematosus (SLE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
Chronic low back pain (CLBP), defined as continuous low back pain lasting for at least three months, represents the largest segment of the chronic pain therapy market and thus is an attractive…
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis…
DRG estimates that 60% of epilepsy patients experience partial-onset seizures (POS). More than two dozen antiepileptic drugs (AEDs) are available in the United States and Europe—the majority of…
Osteoarthritic (OA) pain represents the second largest segment of the chronic pain market and is expected to grow, driven by an aging population and the increasing prevalence of obesity. However, a…
Atrial fibrillation (AF) is the most commonly encountered, sustained cardiac arrhythmia and a condition associated with extreme morbidity, mortality, and cost. The currently available AADs have…
The COPD therapy market is a crowded space in which several LAMAs (e.g., Boehringer Ingelheim’s Spiriva, AstraZeneca’s Tudorza), LABA/ICSFDCs (e.g., GlaxoSmithKline’s Advair and Breo,…
The COPD therapy market is a crowded space in which several LAMAs (e.g., Boehringer Ingelheim’s Spiriva, AstraZeneca’s Tudorza), LABA/ICSFDCs (e.g., GlaxoSmithKline’s Advair and Breo,…
Multiple guidelines recommend treating post-traumatic stress disorder(PTSD) with psychotherapy first line. However, such approaches may not suffice for many patients, necessitating the use of…
Although the schizophrenia drug market is crowded, few, if any, effective therapies are available in the United States and Europe to treat the disease’s negative symptoms (e.g., blunted affect,…
A subset of major depressive disorder (MDD) patients experience suicidal ideation (SID). Because of the potential lethality of SID, SID in MDD is a highly drug-treated condition that uses an array…
The U.S. asthma market has become increasingly crowded with a large number of approved therapies. Those include several LABA/ICSFDCs (i.e., GlaxoSmithKline’s Advair and Breo, AstraZeneca’s…
